Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Dose-escalation Study Evaluate the Safety Tolerability Pharmacokinetics(PK) and Pharmacodynamics(PD) of Relma-cel in Subjects With Moderate to Severe Active Systemic Lupus Erythematosus (SLE)

NCT05765006 is registered in ClinicalTrials.gov with Shanghai Ming Ju Biotechnology Co., Ltd. as lead sponsor.

NCT NCT05765006
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05765006 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Dose-escalation Study Evaluate the Safety Tolerability Pharmacokinetics(PK) and Pharmacodynamics(PD) of Relma-cel in Subjects With Moderate to Severe Active Systemic Lupus Erythematosus (SLE)
Lead sponsor
Shanghai Ming Ju Biotechnology Co., Ltd.
Phase
Phase 1
Overall status
Unknown status
Start date
February 24, 2023
Completion date
December 30, 2025
Enrollment
24 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

systemic lupus erythematosus